copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Mirvetuximab Soravtansine for Ovarian Cancer - WebMD Many people with epithelial ovarian cancer (EOC) respond to treatment at first But cancer comes back, or recurs, in up to 80% of those who get better Over time, a common treatment for advanced
Mirvetuximab Soravtansine-Gynx Approved for Ovarian Cancer Although people with advanced ovarian cancer can initially be treated successfully with platinum-based chemotherapy drugs, the cancer often comes back Platinum-resistant ovarian cancer has proven difficult to treat, but with the Food and Drug Administration’s recent full approval of mirvetuximab soravtansine-gynx (Elahere), some people in this situation now have a new treatment option
FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive . . . Mirvetuximab soravtansine-gynx is the first ADC approved for the treatment of ovarian cancer as well as the first targeted therapy approved for FRα-positive PROC Patients with PROC have limited treatment options, and there is an urgent need for safe and effective new therapies Mirvetuximab soravtansine-gynx was associated with a confirmed
Considering Elahere For Your Ovarian Cancer? Heres What . . . - SurvivorNet RELATED: Ovarian Cancer: Overview Platinum-based chemotherapies, such as cisplatin and carboplatin are a cornerstone of ovarian cancer treatment Far too often, however, these cancers can evolve and become resistant to these traditional medications Ovarian cancer is termed resistant when it returns within 6 months of treatment initiation
ELAHERE® (mirvetuximab soravtansine-gynx) | HCP Website For patients with FRα +, platinum-resistant ovarian cancer, ELAHERE is the first treatment to show statistically significant improvements vs standard single-agent chemotherapy 1-3 * Median PFS: 5 6 months vs 4 0 months, P0 0001 † Median OS: 16 5 months vs 12 7 months, P=0 0046 ‡ ORR: 42% vs 16%, P0 0001 § View the Data
First Targeted Therapy for Platinum-Resistant Ovarian Cancer to Improve . . . This is the first antibody-drug conjugate with proven efficacy in ovarian cancer and the only approved biomarker-driven therapy for platinum-resistant ovarian cancer ” Mirvetuximab soravtansine is an antibody-drug conjugate targeting FR-alpha and conjugated to the highly potenttubulin inhibitor, DM4
Neoadjuvant Vs Adjuvant Treatment Strategies for Ovarian Cancer Murphy is an associate professor of medicine, the senior associate dean of the Graduate Medical Education (GME) program, and program director for the University of Florida Hematology Oncology Fellowship at the University of Florida Health [mirvetuximab soravtansine] is the first ADC in the ovarian cancer space I do not know that we have